Latest News
Inhalon Biopharma Appoints Matthijs Schoots as Vice President, Operations
Durham, North Carolina, September 14, 2026 — Inhalon Biopharma (Inhalon), a clinical-stage company advancing a first-in-class inhaled antibody platform for treating acute respiratory infections (ARI), today announced the appointment of Matthijs Schoots as Vice President, Operations. Mr. Schoots reports to John Whelan, President and Chief Executive Officer.
Mr. Schoots is responsible for portfolio management, strategic planning and day-to-day operations. He brings more than 25 years of experience in clinical operations and program management, much of it in vaccines and infectious disease. He joins Inhalon from Uvax Bio in Cary, North Carolina, where he served as Chief of Staff and Head of Strategic Planning. Previously, at PPD, he led Phase III influenza and RSV programs and directed vaccine operations strategy through the COVID-19 pandemic.
“Matthijs joins Inhalon at an important point in our development,” said John Whelan, President and Chief Executive Officer of Inhalon Biopharma. “He brings the operational discipline to execute across our programs and strengthens our ability to deliver on the promise of inhaled antibody therapy for acute respiratory infections.”
Inhalon Biopharma is developing inhaled antibody therapeutics to treat a range of acute respiratory infections, such as respiratory syncytial virus (RSV), human metapneumovirus (hMPV), influenza, and SARS-CoV-2.
The company’s platform delivers proprietary muco-trapping monoclonal antibodies directly to the airways via a handheld nebulizer, physically crosslinking respiratory viruses to secreted airway mucins and physically eliminating the viruses from the lung through the natural mucus clearance. In a Phase 1b clinical trial, inhaled dosing achieved vastly superior delivery to all parts of the respiratory tract compared to intravenous administration, validating Inhalon’s core premise and vision to transform care for respiratory infections by enabling safe, effective, convenient, self-administered, outpatient treatments.
About Inhalon Biopharma
Inhalon Biopharma, Inc. is a private, clinical-stage company advancing a first-in-class inhaled antibody platform for treating a range of acute respiratory infections. Inhalon Biopharma’s intellectual property includes U.S. and EU patents covering the composition and use of aerosolized muco-trapping antibodies. Inhalon Biopharma is supported by the Thiel Foundation’s Breakout Labs, Cambrian Growth Partners, Berkeley Catalyst Fund, JSR Life Sciences, and Life Science Angels, as well as numerous grants and contracts from the NIH and USAMRDC.
Contact
John Whelan